A 10-Year, Post-marketing, Observational Study to Assess Long Term Safety of HUMIRA® (Adalimumab) in Adult Patients With Chronic Plaque Psoriasis (PS) (ESPRIT)

First published 13/08/2019

Last updated 11/06/2024

EU PAS number:

EUPAS30560

Study

Finalised

Documents

Study protocol

Initial protocol

p10023-protocol-amendment3_Redacted_13Aug2019

English (539.66 KB - PDF)View document

Study results

Study report

P10-023-CSR Abstract_Redacted

English (247.07 KB - PDF)View document

Other information

ENCePP Seal

ENCePP Seal documents

Secondary tabs